[go: up one dir, main page]

BR9714363A - Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas - Google Patents

Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas

Info

Publication number
BR9714363A
BR9714363A BR9714363A BR9714363A BR9714363A BR 9714363 A BR9714363 A BR 9714363A BR 9714363 A BR9714363 A BR 9714363A BR 9714363 A BR9714363 A BR 9714363A BR 9714363 A BR9714363 A BR 9714363A
Authority
BR
Brazil
Prior art keywords
treatment
pyrazole derivatives
substituted pyrazole
circulatory diseases
cardiac circulatory
Prior art date
Application number
BR9714363A
Other languages
English (en)
Inventor
Alexander Straub
Chantal Robyr
Thomas Jaetsch
Achim Feurer
Raimund Kast
Johannes-Peter Stasch
Elisabeth Perzborn
Joachim Huetter
Klaus Dembowsky
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9714363A publication Critical patent/BR9714363A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE PIRAZOL SUBSTITUìDOS PARA O TRATAMENTO DE DOENçAS CIRCULATóRIApara a sua preparação e seu emprego como medicamentos, especialmente como medicamentos para o tratamento de doenças circulatórias cardíacas.
BR9714363A 1996-11-26 1997-11-14 Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas BR9714363A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19649460A DE19649460A1 (de) 1996-11-26 1996-11-26 Neue substituierte Pyrazolderivate
PCT/EP1997/006366 WO1998023619A1 (de) 1996-11-26 1997-11-14 Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen

Publications (1)

Publication Number Publication Date
BR9714363A true BR9714363A (pt) 2000-03-21

Family

ID=7813100

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714363A BR9714363A (pt) 1996-11-26 1997-11-14 Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas

Country Status (25)

Country Link
EP (1) EP0944631B1 (pt)
JP (2) JP4422800B2 (pt)
CN (1) CN1122032C (pt)
AR (1) AR010310A1 (pt)
AT (1) ATE259812T1 (pt)
AU (1) AU729642B2 (pt)
BR (1) BR9714363A (pt)
CA (1) CA2272584C (pt)
CZ (1) CZ185099A3 (pt)
DE (2) DE19649460A1 (pt)
DK (1) DK0944631T3 (pt)
EE (1) EE9900211A (pt)
ES (1) ES2214646T3 (pt)
HU (1) HUP0000562A3 (pt)
ID (1) ID21881A (pt)
IL (1) IL129998A0 (pt)
MX (1) MXPA99004826A (pt)
NO (1) NO992400D0 (pt)
NZ (1) NZ335890A (pt)
PT (1) PT944631E (pt)
SK (1) SK67699A3 (pt)
TR (1) TR199901172T2 (pt)
TW (1) TW403746B (pt)
WO (1) WO1998023619A1 (pt)
ZA (1) ZA9710573B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19827679A1 (de) * 1998-06-22 1999-12-23 Dresden Arzneimittel Adenosinrezeptoraffine, antikonvulsiv und antiallergisch/antiasthmatisch wirkende Pyrazolo[3,4-d]pyrimidine und Verfahren zu deren Herstellung
DE19834045A1 (de) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19920352A1 (de) * 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10021069A1 (de) * 2000-04-28 2001-10-31 Bayer Ag Substituiertes Pyrazolderivat
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
CA2429308C (en) 2000-11-22 2010-09-21 Bayer Aktiengesellschaft Novel lactam-substituted pyrazolopyridine derivatives
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
DE10057754A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Sulfonamid-substituierte Pyrazolopyridinderivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10110749A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10122894A1 (de) 2001-05-11 2002-11-14 Bayer Ag Neue Sulfonat-substituierte Pyrazolopyridinderivate
DE10132416A1 (de) * 2001-07-04 2003-01-16 Bayer Ag Neue Morpholin-überbrückte Pyrazolopyridinderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE10232572A1 (de) * 2002-07-18 2004-02-05 Bayer Ag Neue 2,5-disubstituierte Pyrimidinderivate
DE10244810A1 (de) 2002-09-26 2004-04-08 Bayer Ag Neue Morpholin-überbrückte Indazolderivate
JP4499721B2 (ja) * 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102007015034A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Lactam-substituierte Dicarbonsäuren und ihre Verwendung
DE102007015035A1 (de) 2007-03-29 2008-10-02 Bayer Healthcare Ag Substituierte Dibenzoesäure-Derivate und ihre Verwendung
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028320A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
SI2294066T1 (sl) 2008-04-28 2014-12-31 Janssen Pharmaceutica N.V. Benzoimidazoli kot inhibitorji prolil-hidroksilaze
EP2138178A1 (en) 2008-06-28 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Oxazolidninones for the treatment fo chronic obstructive pulmonary disease (COPD) and/or asthma
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102009004245A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
UY33476A (es) 2010-06-30 2012-02-29 Ironwood Pharmaceuticals Inc Estimuladores de sgc
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
WO2012143510A1 (de) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
BR112014005793A2 (pt) 2011-09-14 2017-03-28 Proximagen Ltd compostos inibidores de enzimas
EP3112363A1 (en) 2011-12-27 2017-01-04 Ironwood Pharmaceuticals, Inc. 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension
SI2847228T1 (sl) 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
EP3094327A1 (en) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
HK1243645A1 (zh) 2015-05-06 2018-07-20 Bayer Pharma Aktiengesellschaft 单独和与pde5抑制剂组合的sgc刺激剂、sgc活化剂用於治疗伴随系统性硬化症(ssc)的指溃疡(du)的用途
LT3325013T (lt) 2015-07-23 2020-11-10 Bayer Pharma Aktiengesellschaft Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas
EA201891416A1 (ru) 2015-12-14 2018-12-28 Айронвуд Фармасьютикалз, Инк. ПРИМЕНЕНИЕ СТИМУЛЯТОРОВ sGC ДЛЯ ЛЕЧЕНИЯ ДИСФУНКЦИИ ЖЕЛУДОЧНО-КИШЕЧНОГО СФИНКТЕРА
WO2017121700A1 (de) * 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
WO2018069148A1 (de) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten
WO2018069126A1 (de) 2016-10-11 2018-04-19 Bayer Pharma Aktiengesellschaft Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
CA3056501A1 (en) 2017-04-11 2018-10-18 Sunshine Lake Pharma Co., Ltd. Fluorine-substituted indazole compounds and uses thereof
MA52616A (fr) 2018-05-15 2021-03-24 Bayer Ag Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses
JP7542518B2 (ja) 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用
WO2020164008A1 (en) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Process for the preparation of porous microparticles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0615542B2 (ja) * 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US4994482A (en) * 1989-07-31 1991-02-19 Bristol-Myers Squibb Company Arylpyrazol derivatives as anti-platelet agents, compositions and use
WO1993023036A1 (fr) * 1992-05-21 1993-11-25 Yoshitomi Pharmaceutical Industries, Ltd. Compose de pyrazole condense optiquement actif, pour le traitement de la thrombocytopenie et de l'erythropenie
JP2928079B2 (ja) * 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
CN1039536C (zh) * 1994-02-28 1998-08-19 永信药品工业股份有限公司 1,3取代缩合吡唑类化合物及其应用和制备方法

Also Published As

Publication number Publication date
NO992400L (no) 1999-05-19
NO992400D0 (no) 1999-05-19
NZ335890A (en) 2001-02-23
EP0944631A1 (de) 1999-09-29
PT944631E (pt) 2004-06-30
DE19649460A1 (de) 1998-05-28
JP4422800B2 (ja) 2010-02-24
SK67699A3 (en) 2000-02-14
HUP0000562A2 (hu) 2000-10-28
ES2214646T3 (es) 2004-09-16
WO1998023619A1 (de) 1998-06-04
JP2001505567A (ja) 2001-04-24
CN1238773A (zh) 1999-12-15
ATE259812T1 (de) 2004-03-15
ID21881A (id) 1999-08-05
IL129998A0 (en) 2000-02-29
HUP0000562A3 (en) 2001-12-28
EE9900211A (et) 1999-12-15
DK0944631T3 (da) 2004-06-07
CN1122032C (zh) 2003-09-24
DE59711321D1 (de) 2004-03-25
CA2272584A1 (en) 1998-06-04
EP0944631B1 (de) 2004-02-18
MXPA99004826A (es) 2008-02-19
JP2010013475A (ja) 2010-01-21
AU729642B2 (en) 2001-02-08
AU5482398A (en) 1998-06-22
HK1023119A1 (en) 2000-09-01
CZ185099A3 (cs) 1999-08-11
ZA9710573B (en) 1998-06-10
TW403746B (en) 2000-09-01
AR010310A1 (es) 2000-06-07
TR199901172T2 (xx) 1999-08-23
CA2272584C (en) 2007-10-16

Similar Documents

Publication Publication Date Title
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
DE69814394D1 (de) Verwendung von levobupivacain
DE69308290D1 (de) Vorsehen einer optimierten schrittmacherfrequenz, die mit den physiologischen erfordernissen des patienten variiert
ITTO950104A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
ITTO950099A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
FI935693A7 (fi) Bifenyylin johdannaiset, niiden valmistus ja käyttö korkean verenpaineen ja sydäntautien hoitoon
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
ES2153906T3 (es) Uso de incienso para el tratamiento de la enfermedad de alzheimer.
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
AU3401093A (en) Therapeutic agent for threatened abortion
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
NL300083I1 (nl) 1-Beta-D-ribofuranosyl-1,2,4-triazool-3-carboxamide voor de bereiding van een geneesmiddel voor de medische behandeling van mensen.
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
DE69007065D1 (de) Verwendung von Diadenosin-5&#39;,5&#39;&#39;&#39;-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
EP1062948A4 (en) DRUGS AGAINST CARDIAC DIASTOLIC DISORDERS
EP0880967A3 (de) Nephroprotektive Arzneimittel
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
UA31266A (uk) Лікувальний засіб &#34;дінальгін&#34;
IT1209508B (it) Nuovi medicinali per il trattamento di malattie cardiache.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time